Prospective Ultrafast MRI Radiomics for Breast Cancer
Ultrafast MRI Radiomics to Classify Histological Factors and Subtypes of Breast Cancer
1 other identifier
observational
225
1 country
1
Brief Summary
The goal of this prospective study is to investigate the performance of ultrafast MRI radiomics in classifying histological factors and subtypes of breast cancer compared with standard MRI among radiologists with varying experience. The written informed consent was obtained from all participant. We extracted 1618 radiomic features from ultrafast and standard contrast-enhanced MRI before treatment. Classification of hormonal receptors, human epidermal growth factor receptor 2, and Ki67 status and subtypes was evaluated using the area under the receiver-operating characteristic curve (AUC) with the DeLong test.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2023
CompletedFirst Submitted
Initial submission to the registry
October 23, 2023
CompletedFirst Posted
Study publicly available on registry
October 27, 2023
CompletedOctober 27, 2023
October 1, 2023
1.2 years
October 23, 2023
October 23, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
The signal intensity of MRI according to histological factors and subtypes of breast cancer
Quantitative image values obtained from ultrafast MRI show similar performance in classifying histological factors and subtypes compared with standard MRI.
Baseline, pre-surgery
Interventions
MRI based classification of breast cancer histological factors and subtypes
Eligibility Criteria
The study population should fulfill the following criteria as follows:(a) histologically confirmed invasive breast cancer, (b) participant consent, and (c) MRI performed before treatment.
You may qualify if:
- Diagnosed with invasive breast cancer
You may not qualify if:
- Diagnosed with other cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bo Kyoung Seo
Ansan, 15355, South Korea
Related Publications (1)
Jeong J, Ham S, Seo BK, Lee JT, Wang S, Bae MS, Cho KR, Woo OH, Song SE, Choi H. Superior performance in classification of breast cancer molecular subtype and histological factors by radiomics based on ultrafast MRI over standard MRI: evidence from a prospective study. Radiol Med. 2025 Mar;130(3):368-380. doi: 10.1007/s11547-025-01956-6. Epub 2025 Jan 25.
PMID: 39862364DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bo Kyoung Seo, MD, PhD
Korea University Ansan Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 23, 2023
First Posted
October 27, 2023
Study Start
October 1, 2021
Primary Completion
November 30, 2022
Study Completion
August 31, 2023
Last Updated
October 27, 2023
Record last verified: 2023-10